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zero, and 2-4 concomitant vaccines, respectively. About 49% of the reports indi-
cated that patients were on concurrentmedications at the time of vaccination, yet;
only 12% of the reports stated that the patients were having coexisting illnesses at
vaccination time. Compared to other vaccines, FLU and MNQ vaccines showed
significantly higher PRR values (10.5, 95%CI 9.4-11.8), (4.7, 95%CI 3.4-6.6).
CONCLUSIONS: It can be postulated that some vaccines are associated with GBS,
especially FLU and MNQ vaccines; underscoring the importance of monitoring pa-
tients for postvaccination signs and symptoms of GBS. While healthcare profes-
sionals are expected to promote vaccination, they should also continue to report
vaccine-associated adverse events to vaccine safety monitoring systems, e.g.
VAERS.
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OBJECTIVES: MRSA skin infections are associated with high morbidity and cost.
Little is known about real-world daptomycin effectiveness in relevant subpopula-
tions. We evaluated outcomes including time to response, duration of antibiotic
therapy, and antibiotic-related hospital length of stay (AR-LOS) in subpopulations
of patients with MRSA skin infections treated with daptomycin. METHODS: Pa-
tients with MRSA skin infections were identified in a retrospective, multicenter,
observational registry describing safety and real-world effectiveness of patients
treated with daptomycin (Cubicin Outcomes Registry and Experience; CORE®). In-
vestigators assessed patient outcome at the end of daptomycin therapy. Subpopu-
lations of interest included those with reduced vancomycin susceptibility (MIC
2mcg/mL), the elderly, diabetics, and those with renal dysfunction. RESULTS: A
total of 137 patients were identified: 53% male, 33% 65yo, 31% diabetic, 6% CrCL
30ml/min. Of patients with vancomycin MICs, 14% were2. Median daptomycin
dose was 6mg/kg; 82% had prior antibiotics (66% of which was vancomycin). Suc-
cess occurred in 94% overall, and was 100% in first-line daptomycin, 93% as second
line. Time to clinical response ranged from 2-4 days with a median of 3 days for
both first and second-line therapy. Median AR-LOS tended to be greater among
subpopulations: those with vancomycin MIC2 [5 vs. 4 days],65 yo [6 vs. 5 days],
diabetics [6 vs. 4 days], and those with CrCL 30 [8 vs. 5 days], compared to those
without each respective condition. Total treatment duration (inpatient and outpa-
tient days) ranged from 7-13 days, depending on clinical subgroup. 11/137 patients
(8.3%) had AEs possibly related to daptomycin; discontinuation due to AEwas 5.8%.
CONCLUSIONS:This evaluation of relevant patient populations providesmeaning-
ful information about real-world effectiveness of daptomycin-treated MRSA skin
infections. AR-LOSwas longer in evaluated subgroups, particularly thosewith CrCL
30ml/min. Additional real-world evaluations, including comparative effective-
ness studies are warranted to further evaluate relevant outcomes in various sub-
populations with MRSA skin infections.
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OBJECTIVES: In diabetes mellitus patients, infected diabetic foot represents 20% of
hospitalizations. In order tominimize health services cost its important to evaluate
which antimicrobial agent could be the best option. The aim of this study was to
conduct a meta-analysis of randomized clinical trials (RCTs) to determine effec-
tiveness and safety of linezolid in the treatment of infected diabetic foot in com-
parisonwith other antimicrobial agents.METHODS:All meta-analysis estimations
were performedwith RCTs based on trials enrolling patientswithmild tomoderate
diabetic foot infections treated with one antimicrobial agent. Effectiveness was
assessed through clinical efficacy (cure/healing); safety and microbiological end-
point indicators. RCTs were searched in December 2009 in Medline, EMBASE, and
the Cochrane Collaboration. Two independent reviewers identified abstracts, se-
lected full articles, and extracted the data. Odds ratios (OR) and weighted mean
differences were calculated. Random effects models were employed in the analy-
seswith RevMan v.5.0 software.RESULTS: 1,528 studieswere reviewed and 19 trials
were finally selected. 13/19 RCTs assessed patients with diabetes mellitus and 6/19
patients with soft tissue infections. Regarding clinical results: linezolid was as
effective as ciproflaxin, ofloxacin and ertapenem; although with higher clinical
efficacy compared to piperacillin/tazobactam (OR 0.52; IC95% 0.340.77 p0.001),
ampicillin/sulbactam (OR 0.40; CI95% 0.270.61 p0.001) and daptomicin (OR 0.45;
IC95% 0.22-0.90 p0.02). Regarding microbiological efficacy, similar results were
estimated (Staph. aureus eradication); however, ertapenem showed a better result
(OR 2.60; CI95% 1.11–6.07 p0.03) than linezolid. Nevertheless, linezolid exhibited
superiority against oxiflacin (OR 0.36; CI95% 0.20-0.65, p0.0006). Frequency of
adverse events was similar in all RCTs. CONCLUSIONS: Currently, little published
evidence exists to define which antimicrobial agent would be the optimum drug
for mild to moderate infected diabetic foot patients. Though, linezolid demon-
strated to be an effective and safe treatment using clinical and microbiological
endpoints.
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OBJECTIVES: In patients with HIV-1, the reduction in RNA copies associated to
treatment has shown a better survival rate. The Highly Active Antiretroviral Ther-
apy (HAART) is the recommended treatment for those patients. As a chronic dis-
ease, the adherence to treatment and adverse effects plays a mayor role. The
objective was to evaluate the efficacy and safety of the combination Efavirenz,
Tenofovir and Emtricitabine (EFV/TDF/FTC) administred once daily compared to
the available treatment combinations in Mexico. METHODS: We conducted a
systematic review using the Cochrane guidelines of randomized clinical trials in
PubMed, EMBASE, LILACS AND Artemisa to compare EFV/TDF/FTC, TDF/
FTCATV/r, TDF/FTCLPV/r, TDF/FTCSQV/r, TDF/FTCFPV/r, ABC/3TCEFV,
ABC/3TCLPV/r, ZDV/3TC/EFV, ZDV/3TCLPV/r in naïve adult patients with
HIV-1 infection. The main outcome variables were RNA HIV-1 copies less than
50/mm3 at 48 and 96 weeks, and grade 2-4 adverse effects at 48 weeks. We used
a random model effects for the pooled analysis. RESULTS: We included 13 arti-
cles, 9 at 48weeks and 4 at 96weeks. The armswere grouped by the three elements
of HAART. The combination EFV/TDF/FTC was the most frequently used (4 and 2
studies at 48 and 96weeks). At 48 and 96weeks the pooled probabilities to have50
RNA copies/ml for EFV/TDF/FTC were 0.784 (CI95%:0.736-0.825; n962) and 0.734
(0.601-0.835; n514); TDF/FTCLPV/r 0.694(0.611-0.766; n958) and 0.633(0.528-
0.726; n788); TDF/FTCATV/r 0.848(0.652-0.943; n488) and 0.743(0.700-0.782;
n440) respectively. The 2-4 grade adverse events rates at 48 weeks were for EFV/
TDF/FTC 0.225(0.074-0.513; n1129); for ABC/3TCEFV 0.316(0.279-0.354; n589); and
for ZDV/3TC/EFV 0.634(0.573-0.691; n254). At 48 weeks the discontinuation rate for
EFV/TDF/FTCwas 0.051(n536); TDF/FTCLPV/r 0.071(n170); and for ZDV/3TCEFV
0.079(n349); the lowestwas TDF/FTCSQV 0.028(n176).CONCLUSIONS: The com-
bination EFV/TDF/FTC is themost studied combination and is clinically effective at
48 and 96 weeks, with good safety profile. The administration once a day improves
the adherence to treatment.
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OBJECTIVES:The global prevalence of hepatitis C virus (HCV) infection is estimated
at over 300million persons. Despite stable prevalence, the economic burden in the
United States (US) is projected to double over the next decade. Less is known,
however, for the rest of the Americas. These epidemiologic and economic data are
critical for decision-makers to project the impacts of HCV treatments. The objec-
tive of this study was to synthesize literature-based estimates of the prevalence
and economic burden of HCV fromCanada,Mexico, Brazil, Argentina, Peru, Colom-
bia, and Venezuela.METHODS: A systematic review was conducted in September
2010 to determine the a) prevalence, and b) resultant economic burden, of HCV.
Two independent reviewers extracted data from articles meeting the inclusion
criteria: from EMBASE, Medline, or the Cochrane databases; focusing on general
population estimates from the target countries; and published since the year 2000.
RESULTS: The search strategy identified 280 abstracts; eight provided general pop-
ulation prevalence estimates. In Brazil, the prevalencewas estimated at 1.4% in Sao
Paulo, and 3.6% in the state of Para. Canadian national surveillance programs es-
timated HCV prevalence at 0.8%; with provincial estimates from 1.3% to 2.0%. Mex-
ican estimates ranged from 0.7% to 2.0%; the national health survey reported a
prevalence of 1.4%. No prevalence estimates were identified for the remaining
countries. Only one study (from Canada) assessed the overall economic burden.
Despite a predicted 14% decrease in prevalence, HCV-related costs were projected
to increase by over 50%, to 158 million dollars annually by 2040. CONCLUSIONS:
HCV prevalence estimates varied from 0.8% to 3.6%, from general population based
studies from Canada, Mexico, and Brazil. Canadian data suggest the economic
burden of HCV is large, and increasing. While these data are useful for decision-
makers, the paucity of data for South America highlights a substantial knowledge
gap.
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In 1996 theUSAdvisoryCommittee on ImmunizationPractices recommendedadmin-
istration of hepatitis A vaccine for those at risk of infection. In 2005, the recommen-
dation was extended to all children and at risk adults. Comprehensive data on hepa-
titis A incidence in amanaged care population has not been evaluated. OBJECTIVES:
To evaluate the incidence of hepatitis A in amanaged care population from 2005 to
2008. METHODS: This was an observational, retrospective cohort study utilizing
medical and pharmacy claims data from January 1, 2005 through December 31,
2008 from the HealthCore Integrated Research Database (HIRDSM). The index date
was defined as date of first diagnostic claim for hepatitis Awithin the intake period.
Patients included were at least 18 years old and had continuous eligibility for at
least 12 months prior to and after index date. RESULTS: A total of 7674 patients
were diagnosed with hepatitis A (51.1% male). Annual incidence was similar for
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genders across years, ranging from 13.3 cases/100,000 person years in females in
2005 to 13.7 cases/100,000 person years in males in 2007. In 2005 and 2006 the
highest incidence was seen in 45 to 54 year olds. In 2007 and 2008 the highest
incidence was in 55 to 64 year olds. Hepatitis A incidence was highest in the West
census regions for each year from 2005-2008. CONCLUSIONS: In a large commer-
cially insured population,we observed similar hepatitis A incidence rates formales
and females across all years examined. Incidence was highest in 45 – 54 and 55 – 64
year olds. The West region had the highest incidence. No evidence of a decline in
incidence presented across the years examined. These results are in line with the
fact that hepatitis A vaccination rates remain low, despite the availability of effec-
tive hepatitis A vaccines, and the increased number of patient populations in
whom hepatitis A vaccination is recommended.
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OBJECTIVES: HIV impairs immune and nervous systems of the individuals and
with progression through different stages, the patients develop a spectrum of neu-
rological complications directly or indirectly related to the viral infection. Since the
introduction of highly active anti-retroviral therapy (HAART), HIV has evolved into
a chronic condition resulting in considerable change in the epidemiology of neu-
rological complications. The objective of the study was to identify and summarize
the incidence and prevalence of neuropathy among HIV positive patients and
subgroups. METHODS: A systematic search of the literature was performed using
MEDLINE® and EMBASE®. The relevant literature was identified based on pre-
defined criteria. Prevalence data were collected from cross-sectional and cohort
studies. Incidence data were collected from cohort and case-control studies.
RESULTS: Thirty-seven studies were included of which there were 23 cohort stud-
ies, 13 cross-sectional studies and 1 case-control study. The prevalence of neurop-
athy among HIV patients derived from 25 studies varied from 1.2% up to 69.4%.
Regarding the development of neuropathy among HIV positive patients, standard-
ized by study duration, the rates per 100 person-years ranged from 0.7 to 39.7.
Among older patients there is a greater risk of neuropathy. The same seems the
case for patients with more severe disease. The association of HIV treatment with
neuropathy is less clear. CONCLUSIONS: Currently available studies providing in-
formation on the incidence and prevalence of neuropathy among HIV patients
suggests a significant burden, but there is a great variation in results across studies.
There is no definitive explanation for the variation however, it underscores the fact
that complexity of the disease, along with absence of standardized diagnostic cri-
teria has considerably influenced the methodologies and outcomes of the studies.
Standardization of an approach to HIV related neuropathy may enhance future
research, allowing for a broader understanding of the condition and its associated
burden.
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OBJECTIVES: Methicillin-resistant Staphylococcus aureus (MRSA) is a gram-positive
bacteria that are resistant to certain -lactam antibiotics and are known as emerg-
ing cause for skin and soft tissue infection. To validate the CDC definition with
antibiotic susceptibility pattern and to identify if any novel risk factors for MRSA
infection are present in the Midwestern population. METHODS: A cross sectional
study was conducted at the academic health care center. Medical records for 100
patients from The Nebraska Medical Center (TNMC) from January 1, 2009 through
December 31, 2009 were collected. MRSA positive patients were investigated and
categorized as hospital-acquired MRSA (HA MRSA) or community- acquired MRSA
(CA MRSA) on the basis of CDC definition. RESULTS: From total 100 MRSA cases of
2009, eighty six percent were HA MRSA and 14% were CA MRSA. Specimen source
(P-value 0.003), race (P-value 0.01), number of present illness (P-value 0.01), and
number of past medical history (P-value 0.005), showed a significant difference
between the twoMRSA. Seventy six percent agreement between the CDCdefinition
and the antibiotic susceptibility definition for CA MRSA and HAMRSA using cipro-
floxacin susceptibility was seen. Multivariate logistic regression concluded that
race (OR 3.76 95% CI - 1.04-14.28), specimen source (OR 0.21 95% CI - 0.03-0.85)
and no. of present illnesses (OR 0.49 95% CI – 0.25-0.86) are the predictors for
MRSA infection in the Midwest. CONCLUSIONS: MRSA infection is a health care-
associated public health problem. Identification of risk factors at early stage can
reduce the negative health outcome, further transmissions, and also help in effi-
cient prevention of this disease. Treatment patterns should be changed depending
on the susceptibility pattern of the organism. Research is needed to identify proper
treatment regimens for the Midwestern population.
Infection – Cost Studies
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OBJECTIVES: To calculate the impact of abacavir/lamivudine on the Mexican drug
budget in 2010 and to forecast its impact over the following 5 years. METHODS: A
budget impact model (BIM) of HIV infected patients was developed to evaluate the
costs of abacavir/lamivudina versus emtricitabina/tenofovir and lamivudina/zid-
ovudine from the Mexican Health Care perspective. The BIM was calculated by
triangulating information derived frommultiple Mexican data sources. The model
is based on disease prevalence, drug acquisition cost and sales forecasting data
specific to Mexico. The projected population and incidence of VIH was obtained
from the literature. The (BIM)was based on two scenarios reflecting different levels
of growth in the number of patient. The study was conducted from the Mexican
Healthcare perspective. The average budget impact in the first 5 years (startup
phase) and subsequent years (steady state) was assessed in US dollars. Future costs
were discounted at 5% per recommendations for analyses in Mexico. RESULTS:
Increasing utilization of abacavir/lamivudine, from 5% to 60% over 5 years period
resulted in an net cost saving during the initial startup phase of $ 24millions and $
157 millions to the steady state. These reductions translated to a total net cost
saving of $ 437 millions “in 2010 dollars” over 5 years. The total direct costs de-
creased progressively at the end of the five-year period due to decreased acquisi-
tion drug costs. Sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values of the model parameters.
CONCLUSIONS: The budget impact analysis of abacavir/lamivudine for HIV start-
ing in 2010 shows a positive impact on the health budget because it saves costs
after 2010 and produces a net benefit from the beginning of treatment. Abacavir/
lamivudina led to important cost savings due to its lower drug acquisition cost.
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OBJECTIVES: To design an economic cost comparison model of daptomycin, com-
pared with standard therapy (based on vancomycin) in the treatment of bactere-
mia due to Staphylococcus aureus (both methicillin-resistant and non-resistant
strains) in Colombia.METHODS:We designed a decision tree model (TreeAge soft-
ware) based on one large randomized non-inferiority clinical trial (Fowler, N Engl
J Med, 2006), applying local (direct) costs obtained from a university hospital in
Bogota. We used third party payer perspective; timeframe 6 weeks from the end of
antibiotic therapy. We separately estimated antibiotic costs, hospitalization costs,
“other” hospital costs (which include non-antibiotic drugs, lab tests, medical im-
aging,medical visits, etc.) and total costs. Exchange rate: 1934 Colombian pesos per
US$ (as of July, 2010). RESULTS: When antibiotic costs are considered separately,
thesewere higher in the daptomycin branch (US$3821 vs. US$3366). This difference
disappears when total costs are calculated (US$9317 vs. US$9492). Hospitalization
costs were US$1701 for daptomycin and US$1783 for standard therapy, while
“other” costs were US$3795 and US$4343, respectively. On the other hand, dapto-
mycin therapy is associated with a lower incidence of acute renal failure (NNT 
17). CONCLUSIONS: If the two therapies compared have similar effectiveness, at
similar costs, the discriminating factor in medical decision making should be
safety. Choosing daptomycin instead of standard care (vancomycin) in adult pa-
tient with bacteremia due to S. aureus makes clinical and economic sense.
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OBJECTIVES: Extended intramammary treatment of bovine clinical mastitis (CM)
results in better cure rates but should be balanced economically against higher
drug costs and extra waste of saleablemilk because of a longermilk discard period.
This study aimed to compare licensed extended treatment with pirlimycin (5 infu-
sions q.d.) to shorter licensed treatments with cephapirin (2 infusions b.i.d.) and
hetacillin (3 infusions q.d.) in dairy cows with CM caused by gram-positive patho-
gens (gramCM), accounting for approximately 28% of all bovine mastitis cases in
the US.METHODS:Adecision treewas developed inMS Excel, considering first and
recurrent CM episodes, culling and death of dairy cows with gramCM over an
entire lactation period of 305 days. The model considered costs and losses associ-
atedwith CM and its treatment, culling or deaths aswell as income generated from
saleable milk production and sold cows. Prices and cost data were compiled from
public sources (US-2010, perspective of the producer); efficacy data were derived
from published studies. All input parameters were varied extensively in one-way
sensitivity analyses. RESULTS: Per treated cow, the income frommilk production
over one lactation period was $3051.72 (pirlimycin), $3054.66 (cephapirin), and
$3049.21 (hetacillin). Costs associated with the disease and treatment totaled to
$226.78 (pirlimycin), $236.84 (cephapirin), and $238.34 (hetacillin). As such, ex-
tended treatment with pirlimycin results in a higher profit margin of $7.12 and
$14.07 per treated cow and per lactation, compared to 2 to 3 infusions with
cephapirin and hetacillin, respectively. Fewer deaths or culling occurred with
pirlimycin. Outcomes were most sensitive to cure rates of first mastitis
episodes. CONCLUSIONS: With US 2010 cost/price data, the economic drawbacks
of extendedmastitis treatment weremore than offset by better efficacy with 5-day
pirlimycin treatment compared to 2 to 3 infusions with cephapirin or hetacillin.
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